Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2023, with the report dated July 3, 2023. The filing serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the company's total voting rights and capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data as of June 30, 2023.
- Issued Share Capital: 4,312,071,604 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 217,068,169 Ordinary Shares.
- Total Voting Rights: 4,095,003,435.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports a static snapshot of share capital and voting rights as of June 30, 2023, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification regarding share counts and does not contain operational or strategic commentary.
Important Facts for Investors to Verify
- Verify the total number of voting rights (4,095,003,435) to determine if notification thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (217,068,169) when calculating diluted share counts.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.